Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Articles|November 2, 2018
- Pharmaceutical Technology-11-02-2018
- Volume 42
- Issue 11
Detachable AODD Pump
Wilden, part of PSG, a Dover company, released its new 6 mm (1/4”) Velocity Series air-operated double-diaphragm (AODD) pump.
Advertisement
Wilden, part of PSG, a Dover company, released its new 6 mm (1/4”) Velocity Series air-operated double-diaphragm (AODD) pump. The V2550 Velocity Series pump features a detachable mounting foot, providing adaptable mounting capabilities suitable for all small-dosing applications.
The company reports that the pump can be reoriented by loosening a single screw. The design provides the user with multiple mounting options while allowing the pump to fit into restricted spaces, a critical consideration for original equipment manufacturer systems and skids. The pump’s design also eliminates the effects of torque decay and delivers improved dry suction lift at all operating parameters for better priming under a variety of system conditions. Additionally, the pumps feature an interchangeable footprint with competitor and previous company designs.
This pump series comes equipped with a simple air distribution system (ADS) with two moving parts that reduce the risk of downtime, according to the company. Wilden Velocity Series pumps can handle suction lifts from 10–14 feet. These pumps are available in polypropylene and PVDF construction, as well as an Accu-Flo (solenoid) option.
Articles in this issue
almost 8 years ago
Guidelines on Integral Drug-Device Combinationsalmost 8 years ago
Advanced Paddle Blender for Labsalmost 8 years ago
Custom Multi-Shaft Mixeralmost 8 years ago
Bioimaging Molecular Probesalmost 8 years ago
User Requirements Specifications–How Difficult Can It Be?almost 8 years ago
Single-Use Bioprocessing Equipment Trends and Adoption by CMOsalmost 8 years ago
Innovations in Prefilled Syringes for Biologic Drugsalmost 8 years ago
Media Requirements for Different Cell SourcesAdvertisement
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
What the Olanzapine Depot Approval Means for CMC Teams
3
Complying with International Pharmacopoeias
4
PharmTech AI Pulse Check: Availability Bias Threatens AI Regulatory Reviews
5